Viewing Study NCT05862194

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:38 AM
Ignite Modification Date: 2026-07-13 @ 2:18 PM
Study NCT ID: NCT05862194
Status: COMPLETED
Last Update Posted: 2023-08-22
First Post: 2023-05-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
Sponsor: Yuhan Corporation
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None EGFR Sensitizing Mutation View
None T790M mutation View
None EGFR TKI View
None Second-line View
None YH25448 View
None External Comparator View
None Retrospective View
None Advanced Non-Small Cell Lung Cancer View
None Lazertinib View